Lynn D. Kramer

Lecanemab in Early Alzheimer’s Disease

Christopher H. van Dyck, Chad J. Swanson, Paul Aisen et al. · New England Journal of Medicine · 2022 · 4.7K citations · Full text

Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations

Robert H. Dworkin, Dennis C. Turk, Kathleen W. Wyrwich et al. · Journal of Pain · 2007 · 3.2K citations

Immpact Recommendations, Pain Research, Pain Therapy +12

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Chad J. Swanson, Yong Zhang, Shobha Dhadda et al. · Alzheimer s Research & Therapy · 2021 · 757 citations · Full text

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

Eric McDade, Jeffrey L. Cummings, Shobha Dhadda et al. · Alzheimer s Research & Therapy · 2022 · 260 citations · Full text

Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase <scp>III</scp> studies

Bernhard J. Steinhoff, Elinor Ben‐Menachem, Philippe Ryvlin et al. · Epilepsia · 2013 · 257 citations · Full text